Q2 results
30.07.2010
Sanofi-Aventis Chief Executive Chris Viehbacher delivered forecast-beating second quarter results on
Thursday as he prepared to bid $18.7 billion for U.S biotech group Genzyme.
Viehbacher would not comment on any upcoming deal, and pledged instead to stay disciplined on the takeover front.
Sources told Reuters late on Wednesday that Sanofi plans to make a formal offer of up to $18.7 billion, or $70 per share, for Genzyme as it seeks to replenish its drug pipeline and make up for the loss of patent protection on blockbuster drugs in the years through 2013.
more30.07.2010
Celanese Corp said on Thursday that second-quarter profit rose 50 percent as the improving economy continued to increase demand for its products, and the chemical maker raised its full-year outlook.
Net income rose to $160 million, or $1.01 per share, from $107 million, or 69 cents per share, a year earlier.
Excluding one-time items, the company posted profit of $1.12 per share.
Revenue at the Dallas-based company rose 22 percent to $1.52 billion. Analysts expected $1.46 billion.
more